Acquisition by Saadi Ryan H. of 2607 shares of Tevogen Bio at 0.7671 subject to Rule 16b-3
| TVGN Stock | 1.31 0.06 4.38% |
About 64% of Tevogen Bio's investor base is looking to short. The analysis of the overall investor sentiment regarding Tevogen Bio Holdings suggests that many traders are alarmed. Tevogen Bio's investing sentiment overview a quick insight into current market opportunities from investing in Tevogen Bio Holdings. Many technical investors use Tevogen Bio Holdings stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Tevogen |
Filed transaction by Tevogen Bio Holdings Director, 10 Percent Owner, Officer: Chief Executive Officer. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Cash Flow Correlation
Tevogen Bio's cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Tevogen Bio's relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Tevogen Bio Fundamental Analysis
We analyze Tevogen Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tevogen Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tevogen Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
Tevogen Bio is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Tevogen Bio Holdings Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Tevogen Bio stock to make a market-neutral strategy. Peer analysis of Tevogen Bio could also be used in its relative valuation, which is a method of valuing Tevogen Bio by comparing valuation metrics with similar companies.
Peers
Tevogen Bio Related Equities
| AEO | American Eagle | 3.55 | ||||
| VSCO | Victorias Secret | 2.24 | ||||
| KTB | Kontoor Brands | 1.19 | ||||
| TS | Tenaris SA | 0.63 | ||||
| SCVL | Shoe Carnival | 0.45 | ||||
| SKX | Skechers USA | 0.17 | ||||
| NBR | Nabors Industries | 0.11 | ||||
| DKDRF | Delek Drilling | 2.20 |
Check out Tevogen Bio Hype Analysis, Tevogen Bio Correlation and Tevogen Bio Performance. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tevogen Bio. If investors know Tevogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tevogen Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Return On Assets (0.83) |
The market value of Tevogen Bio Holdings is measured differently than its book value, which is the value of Tevogen that is recorded on the company's balance sheet. Investors also form their own opinion of Tevogen Bio's value that differs from its market value or its book value, called intrinsic value, which is Tevogen Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tevogen Bio's market value can be influenced by many factors that don't directly affect Tevogen Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tevogen Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tevogen Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tevogen Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.